Portola Pharmaceuticals, Inc. [NASDAQ:PTLA]: Analyst Rating and Earnings

Equities traders frequently stay up to date regarding what leading market analysts think about a possible stock buy. As it relates to Portola Pharmaceuticals, Inc. [PTLA], the latest mean analyst recommendation that’s publicly available is from the fiscal three-month period ending in December. On average, stock market experts give PTLA an Outperform rating. Its stock price has been found in the range of 14.81 to 44.25. This is compared to its latest closing price of $26.27.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Portola Pharmaceuticals, Inc. [PTLA] is sitting at 1.83. This is compared to 1 month ago, when its average rating was 1.83.

For the quarter ending in Mar-19 Portola Pharmaceuticals, Inc. [PTLA] generated $0.02 billion in sales. That’s 15.56% higher than the average estimate of $0.02 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Thu 8 Aug (In 56 Days).

Fundamental Analysis of Portola Pharmaceuticals, Inc. [PTLA]

Now let’s turn to look at profitability: with a current Operating Margin for Portola Pharmaceuticals, Inc. [PTLA] sitting at -860.50 and its Gross Margin at +48.71.

Turning to investigate this organization’s capital structure, Portola Pharmaceuticals, Inc. [PTLA] has generated a Total Debt to Total Equity ratio of 252.39. Similarly, its Total Debt to Total Capital is 71.62, while its Total Debt to Total Assets stands at 57.74. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 238.05, and its Long-Term Debt to Total Capital is 67.55. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -5.10. The Enterprise Value to Sales for this firm is now 31.34, and its Total Debt to Enterprise Value stands at 0.19. Portola Pharmaceuticals, Inc. [PTLA] has a Price to Book Ratio of 14.71.

Shifting the focus to workforce efficiency, Portola Pharmaceuticals, Inc. [PTLA] earns $123,858 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 4.11 and its Total Asset Turnover is 0.08. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 5.01 and its Current Ratio is 5.12. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Portola Pharmaceuticals, Inc. [PTLA] has 67.63M shares outstanding, amounting to a total market cap of $1.76B. Its stock price has been found in the range of 14.81 to 44.25. At its current price, it has moved by -41.22% from its 52-week high, and it has moved 75.62% from its 52-week low.

This stock’s Beta value is currently 2.34, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 29.94. This stock, according to these metrics, is currently Oversold.

Conclusion: Is Portola Pharmaceuticals, Inc. [PTLA] a Reliable Buy?

Portola Pharmaceuticals, Inc. [PTLA] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.